Biblioteca CRAI Dulce Chacón - Universidad Europea de Madrid

CRAI Library - Madrid
Your cart is empty.
My folder ( items) | My account
Image from Google Jackets

Gastric cancer prewarning and early diagnosis system / Daxiang Cui, editor.

Contributor(s): Cui, Daxiang.
Material type: materialTypeLabelE-bookSeries: (Translational Medicine Research, 2451-991X).Publisher: [Lugar de publicación no identificado] : Springer, 2017Edition: 1st ed. 2017.Description: 1 recurso en línea.ISBN: 9402409513; 9789402409512.Subject: BiotecnologíaOnline resources: Acceso a este recurso digital (usuarios Universidad Europea de Madrid)Digital Resources
Contents:
Preface; Contents; Chapter 1: Background of Gastric Cancer Prewarning and Early Diagnosis System; 1.1 Current Clinical Status of Gastric Cancer; 1.2 Main Diagnostic Methods for Gastric Cancer in the Clinical Setting; 1.2.1 Endoscopy; 1.2.2 Imaging Diagnosis; 1.2.3 Histopathological Examination; 1.2.4 Serological Biomarker Examination; 1.3 Concept of Gastric Cancer Prewarning and Early Diagnosis System; References; Chapter 2: Human Serum Protein Markers for Gastric Cancer Detection; 2.1 Introduction; 2.2 Broad-Spectrum Tumor Serum Markers in the Detection of Gastric Cancer; 2.2.1 CEA.
2.2.2 CA19-92.2.3 CA125; 2.2.4 AFP; 2.2.5 M2-Pyruvate Kinase; 2.3 Gastric Secreted Protein as Serum Markers of Gastric Cancer; 2.3.1 PGI; 2.3.2 PGII; 2.3.3 Gastrin 17; 2.3.4 TFF3; 2.4 Gastric Infection and Gastric Cancer-Associated Antibodies; 2.4.1 H. pylori Antibody; 2.4.2 CagA Antibody; 2.4.3 p53 Antibody; 2.4.4 Anti-parietal Cell Antibody; 2.5 Inflammation Signaling Molecules in the Diagnosis of Gastric Cancer; 2.5.1 SAA (Serum Amyloid A); 2.5.2 MIF (Macrophage Migration Inhibitory Factor); 2.5.3 Leptin; 2.5.4 Dickkopf; 2.5.5 Olfactomedin 4; 2.5.6 VAP-1 (Vascular Adhesion Protein-1).
2.6 Protease and Protease Inhibitors in the Diagnosis of Gastric Cancer2.6.1 UPA; 2.6.2 Cathepsin B; 2.6.3 HMW Kininogen; 2.7 Apoptosis-Related Molecules; 2.7.1 Cytokeratin 18; 2.8 Cell Division-Related Molecules; 2.8.1 RegIV; 2.8.2 S100A6; 2.8.3 IPO-38; 2.9 Plasma Coagulation Factors; 2.9.1 Thrombin Light Chain A; 2.9.2 Fibrinopeptide A; 2.10 Conclusions; References; Chapter 3: Screening and Detection of Gastric Cancer Circulating MicroRNA Biomarkers; 3.1 MicroRNA and Gastric Cancer; 3.1.1 MicroRNA; 3.1.2 MicroRNA and Gastric Cancer; 3.2 Circulating MicroRNA Biomarkers for Gastric Cancer.
3.2.1 Background3.2.2 Advantages on Circulating MicroRNA Biomarkers; 3.2.3 Correlation Between Tissue miRNAs and Circulating miRNAs; 3.2.4 Challenges on Screening of Circulating MicroRNA Biomarkers; 3.2.5 Circulating MicroRNA Biomarkers for Gastric Cancer; 3.2.6 Conclusions and Prospects; 3.3 Nanoparticle-Based Optical Detection of MicroRNA; 3.3.1 Background; 3.3.2 Characteristics of MicroRNA Detection; 3.3.3 Fluorescence-Based MicroRNA Detection; 3.3.3.1 Quantum Dots; 3.3.3.2 Silver Nanoclusters; 3.3.3.3 Magnetic Nanoparticles and Others; 3.3.4 Scattering-Based MicroRNA Detection.
3.3.4.1 SERS3.3.4.2 Other Scattering; 3.3.5 Colorimetry-Based MicroRNA Detection; 3.3.6 Conclusions and Outlook; References; Chapter 4: Screening and Identification of Biomarkers from Gastric Cancer Saliva Metabolites; 4.1 Introduction; 4.2 Molecular Identification in Saliva of Gastric Cancer Patients; 4.3 Biomarkers in Saliva of Gastric Cancer Patients and Metabolic Characteristics; 4.4 Diagnosis of Gastric Cancer Using the Identified Biomarkers; 4.5 Saliva Markers for Gastric Cancer Detection; References.
Abstract: The book explores recent developments in the application of nanotechnology in the early detection of gastric cancer. It discusses various aspects, such as screening for gastric cancer-associated biomarkers; establishing new ultrasensitive detection methods based on nanoparticle labeling and nanoeffects; developing a new generation of nanodevices for high-throughput examination of serum and breath biomarkers; developing multifunctional nanoprobes for targeted imaging and simultaneous therapy of gastric cancer; evaluating the biosafety of multifunctional nanoprobes; and the establishment of a pre-warning and early diagnosis system. It also presents clinical applications and prospects. The book provides a valuable reference for researchers in nanomedicine and clinicians involved in gastric cancer and radiology.
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Collection Call number Status Date due Barcode Item holds
LIBRO-E NO PRÉSTAMO LIBRO-E NO PRÉSTAMO Madrid Digital Acceso Electrónico (UEM) Ciencias de la Salud RC280.S8 G378 2017 EB (Browse shelf(Opens below)) Acceso electrónico eBook.20023891
Total holds: 0

SpringerLink Springer Biomedical and Life Sciences eBooks 2017 English+International

Preface; Contents; Chapter 1: Background of Gastric Cancer Prewarning and Early Diagnosis System; 1.1 Current Clinical Status of Gastric Cancer; 1.2 Main Diagnostic Methods for Gastric Cancer in the Clinical Setting; 1.2.1 Endoscopy; 1.2.2 Imaging Diagnosis; 1.2.3 Histopathological Examination; 1.2.4 Serological Biomarker Examination; 1.3 Concept of Gastric Cancer Prewarning and Early Diagnosis System; References; Chapter 2: Human Serum Protein Markers for Gastric Cancer Detection; 2.1 Introduction; 2.2 Broad-Spectrum Tumor Serum Markers in the Detection of Gastric Cancer; 2.2.1 CEA.

2.2.2 CA19-92.2.3 CA125; 2.2.4 AFP; 2.2.5 M2-Pyruvate Kinase; 2.3 Gastric Secreted Protein as Serum Markers of Gastric Cancer; 2.3.1 PGI; 2.3.2 PGII; 2.3.3 Gastrin 17; 2.3.4 TFF3; 2.4 Gastric Infection and Gastric Cancer-Associated Antibodies; 2.4.1 H. pylori Antibody; 2.4.2 CagA Antibody; 2.4.3 p53 Antibody; 2.4.4 Anti-parietal Cell Antibody; 2.5 Inflammation Signaling Molecules in the Diagnosis of Gastric Cancer; 2.5.1 SAA (Serum Amyloid A); 2.5.2 MIF (Macrophage Migration Inhibitory Factor); 2.5.3 Leptin; 2.5.4 Dickkopf; 2.5.5 Olfactomedin 4; 2.5.6 VAP-1 (Vascular Adhesion Protein-1).

2.6 Protease and Protease Inhibitors in the Diagnosis of Gastric Cancer2.6.1 UPA; 2.6.2 Cathepsin B; 2.6.3 HMW Kininogen; 2.7 Apoptosis-Related Molecules; 2.7.1 Cytokeratin 18; 2.8 Cell Division-Related Molecules; 2.8.1 RegIV; 2.8.2 S100A6; 2.8.3 IPO-38; 2.9 Plasma Coagulation Factors; 2.9.1 Thrombin Light Chain A; 2.9.2 Fibrinopeptide A; 2.10 Conclusions; References; Chapter 3: Screening and Detection of Gastric Cancer Circulating MicroRNA Biomarkers; 3.1 MicroRNA and Gastric Cancer; 3.1.1 MicroRNA; 3.1.2 MicroRNA and Gastric Cancer; 3.2 Circulating MicroRNA Biomarkers for Gastric Cancer.

3.2.1 Background3.2.2 Advantages on Circulating MicroRNA Biomarkers; 3.2.3 Correlation Between Tissue miRNAs and Circulating miRNAs; 3.2.4 Challenges on Screening of Circulating MicroRNA Biomarkers; 3.2.5 Circulating MicroRNA Biomarkers for Gastric Cancer; 3.2.6 Conclusions and Prospects; 3.3 Nanoparticle-Based Optical Detection of MicroRNA; 3.3.1 Background; 3.3.2 Characteristics of MicroRNA Detection; 3.3.3 Fluorescence-Based MicroRNA Detection; 3.3.3.1 Quantum Dots; 3.3.3.2 Silver Nanoclusters; 3.3.3.3 Magnetic Nanoparticles and Others; 3.3.4 Scattering-Based MicroRNA Detection.

3.3.4.1 SERS3.3.4.2 Other Scattering; 3.3.5 Colorimetry-Based MicroRNA Detection; 3.3.6 Conclusions and Outlook; References; Chapter 4: Screening and Identification of Biomarkers from Gastric Cancer Saliva Metabolites; 4.1 Introduction; 4.2 Molecular Identification in Saliva of Gastric Cancer Patients; 4.3 Biomarkers in Saliva of Gastric Cancer Patients and Metabolic Characteristics; 4.4 Diagnosis of Gastric Cancer Using the Identified Biomarkers; 4.5 Saliva Markers for Gastric Cancer Detection; References.

The book explores recent developments in the application of nanotechnology in the early detection of gastric cancer. It discusses various aspects, such as screening for gastric cancer-associated biomarkers; establishing new ultrasensitive detection methods based on nanoparticle labeling and nanoeffects; developing a new generation of nanodevices for high-throughput examination of serum and breath biomarkers; developing multifunctional nanoprobes for targeted imaging and simultaneous therapy of gastric cancer; evaluating the biosafety of multifunctional nanoprobes; and the establishment of a pre-warning and early diagnosis system. It also presents clinical applications and prospects. The book provides a valuable reference for researchers in nanomedicine and clinicians involved in gastric cancer and radiology.

There are no comments on this title.

to post a comment.
Share